OnKure Therapeutics, Inc.
General ticker "OKUR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $55.3M (TTM average)
OnKure Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -1.3%.
Estimated limits based on current volatility of 4.8%: low 2.85$, high 3.14$
Factors to consider:
- Current price 43.7% below estimated low
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [5.35$, 17.43$]
- 2025-12-31 to 2026-12-31 estimated range: [4.95$, 15.87$]
Financial Metrics affecting the OKUR estimates:
- Negative: with PPE of -1.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -46.40 <= 0.33
- Positive: Investing cash flow per share per price, % of 14.41 > -0.66
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Shareholder equity ratio, % of 90.36 > 63.39
Short-term OKUR quotes
Long-term OKUR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $29.77MM | $36.93MM | $54.39MM |
| Operating Income | $-29.77MM | $-36.93MM | $-54.39MM |
| Non-Operating Income | $0.25MM | $1.62MM | $1.71MM |
| Interest Expense | $0.00MM | $0.00MM | $0.30MM |
| R&D Expense | $25.86MM | $32.12MM | $43.80MM |
| Income(Loss) | $-29.51MM | $-35.31MM | $-52.67MM |
| Profit(Loss)* | $-29.51MM | $-35.31MM | $-52.67MM |
| Stockholders Equity | $-54.42MM | $-101.84MM | $103.83MM |
| Assets | $16.00MM | $35.73MM | $114.91MM |
| Operating Cash Flow | $-26.95MM | $-34.55MM | $-51.12MM |
| Capital expenditure | $1.13MM | $0.25MM | $0.05MM |
| Investing Cash Flow | $-1.13MM | $-0.25MM | $15.87MM |
| Financing Cash Flow | $26.46MM | $53.12MM | $116.13MM |
| Earnings Per Share** | $-2.21 | $-2.65 | $-3.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.